Molecular Partners AG (MOLN) Stock Statistics & Valuation Metrics

Molecular Partners AG has a market cap or net worth of CHF132.83M. The enterprise value is CHF2.67M.

Molecular Partners AG has 40,374,640 shares outstanding. The number of shares has decreased by -2.65% in one year.

Molecular Partners AG’s return on equity (ROE) is -0.38 and return on invested capital (ROIC) is -41.10%.

The current PE Ratio of Molecular Partners AG is -2.56. Molecular Partners AG’s PEG ratio is 0.16.

In the last 12 months, Molecular Partners AG had revenue of 4.97M and earned -54.04M in profits. Earnings per share was -1.59.

In the last 12 months, operating cash flow was -56.79M and capital expenditures -723.00K, giving a free cash flow of -57.51M billion.

Molecular Partners AG pays an annual dividend of ―, resulting in a dividend yield of ―

Molecular Partners AG upcoming earnings date is Aug 25, 2025, TBA Not Confirmed.

Molecular Partners AG as a current ratio of 14.31, with Debt / Equity ratio of 1.73%

In the past 12 months, Molecular Partners AG has paid 2.00K in taxes.

Molecular Partners AG EV to EBITDA ratio is -1.49, with an EV/FCF ratio of -1.28.

Molecular Partners AG has CHF149.44M in cash and marketable securities with CHF0.00 in debt, giving a net cash position of -CHF147.00M billion.

Gross margin is -447.10%, with operating margin of -1231.73%, and net profit margin of -1087.38%.

The average price target for Molecular Partners AG is CHF9.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy